AstraZeneca announces management changes

The president and chief executive officer at AstraZeneca’s biologics business unit has announced he is leaving the company in the end of July.

Dave Mott will be succeeded at MedImmune by Tony Zook on an interim basis. Mr Zook is currently the chief executive officer of AstraZeneca’s North American business and executive vice-president of Global Marketing.

David Brennan, chief executive officer of AstraZeneca, said: “Under Dave Mott’s leadership, the team at MedImmune has built a unique capability to discover, develop and deliver innovative biologic treatments ? an important element of AstraZeneca’s future strategy.”

The company will carry on creating new vaccines and medicines to tackle diseases, he added.

Since July 2007, AstraZeneca has seen the integration of Cambridge Antibody Technology and the company’s own biologic resources into MedImmune.

AstraZeneca is a pharmaceutical company which focuses on six main areas of health related problems including cardiovascular, cancer, infection, gastrointestinal and respiratory & inflammation.